Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVFM NYSE:OGEN NASDAQ:PTPI NASDAQ:TFFP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.01-3.1%$0.01$0.01▼$0.02$1.12M-0.99410,480 shs506,578 shsOGENOragenics$1.15-3.4%$2.21$1.03▼$42.00$946K0.65334,245 shs72,904 shsPTPIPetros Pharmaceuticals$0.03-1.3%$0.03$0.02▼$16.25$953K1.565.13 million shs744,992 shsTFFPTFF Pharmaceuticals$0.07$0.06$0.06▼$3.23$289KN/AN/AN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences-3.09%-2.08%-4.08%+2.17%-6.00%OGENOragenics-3.36%-0.86%-19.01%-80.83%-97.87%PTPIPetros Pharmaceuticals-1.29%+12.92%+7.37%-77.01%-99.61%TFFPTFF Pharmaceuticals0.00%0.00%0.00%0.00%-96.81%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVFMEvofem Biosciences1.7421 of 5 stars0.05.00.04.82.40.00.0OGENOragenics0.3632 of 5 stars0.04.00.00.01.90.00.0PTPIPetros Pharmaceuticals0.2318 of 5 stars0.03.00.00.00.00.80.6TFFPTFF PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVFMEvofem Biosciences 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/APTPIPetros Pharmaceuticals 0.00N/AN/AN/ATFFPTFF Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVFMEvofem Biosciences$11.39M0.10N/AN/A($2.64) per share0.00OGENOragenicsN/AN/AN/AN/A$0.61 per shareN/APTPIPetros Pharmaceuticals$5.11M0.19N/AN/A$4.04 per share0.01TFFPTFF Pharmaceuticals$730K0.40N/AN/A$4.04 per share0.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVFMEvofem Biosciences$52.98M-$0.05N/A∞N/A-46.42%-91.97%-61.93%N/AOGENOragenics-$20.66M-$21.42N/A∞N/AN/A-2,087.95%-486.56%N/APTPIPetros Pharmaceuticals-$8.16M-$60.87N/A∞N/AN/A-78.22%-23.50%N/ATFFPTFF Pharmaceuticals-$21.24M-$6.44N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVFMEvofem BiosciencesN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/APTPIPetros PharmaceuticalsN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVFMEvofem BiosciencesN/A0.110.09OGENOragenicsN/A1.931.93PTPIPetros Pharmaceuticals1.580.850.74TFFPTFF PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVFMEvofem Biosciences0.22%OGENOragenics18.71%PTPIPetros Pharmaceuticals12.34%TFFPTFF Pharmaceuticals15.25%Insider OwnershipCompanyInsider OwnershipEVFMEvofem Biosciences0.01%OGENOragenics4.90%PTPIPetros Pharmaceuticals12.25%TFFPTFF Pharmaceuticals4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableOGENOragenics5823,00010.98 millionN/APTPIPetros Pharmaceuticals2031.16 million9.93 millionNot OptionableTFFPTFF Pharmaceuticals194.44 million4.24 millionOptionableTFFP, EVFM, OGEN, and PTPI HeadlinesRecent News About These CompaniesTFF Pharmaceuticals approves dissolution planMarch 8, 2025 | uk.investing.comTFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC DeregistrationFebruary 6, 2025 | prnewswire.comTFF Pharmaceuticals Inc (TFFP) Stock: A Deeper Look at Its True PotentialDecember 12, 2024 | bovnews.comBThe TFFP Stock Mystery: Why Did TFFP Plunge Today?December 6, 2024 | bovnews.comBTFF Pharmaceuticals Inc (TFFP) Stock: More Robust Than the Numbers Suggest?November 23, 2024 | bovnews.comBStock Shock: The Unpredictable Rise and Fall of TFFP—What’s Driving the Drama?November 20, 2024 | bovnews.comBTFFP Unveiled: The Shocking Truth Behind TFF Pharmaceuticals Inc’s Latest Stock MovementsNovember 19, 2024 | bovnews.comBU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%November 15, 2024 | msn.comTFF Pharmaceuticals (TFFP) Takes a Dark Turn: What’s Next for Investors?November 15, 2024 | bovnews.comBTFF Pharmaceuticals Shares Fall 66%; Company to Wind DownNovember 14, 2024 | marketwatch.comTFF Pharmaceuticals terminates employees, to wind down operationsNovember 14, 2024 | markets.businessinsider.comTFF Pharmaceuticals to Dissolve and Liquidate AssetsNovember 14, 2024 | markets.businessinsider.comTFF Pharmaceuticals, Inc. Announces Termination of Employees and Wind Down of OperationsNovember 14, 2024 | quiverquant.comQTFF Pharmaceuticals Announces It Will Wind Down OperationsNovember 14, 2024 | globenewswire.comTFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comTFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's WhyOctober 8, 2024 | zacks.comTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | finanznachrichten.deTFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | markets.businessinsider.comPost-COVID Trends in Biopharma Contract ManufacturingSeptember 25, 2024 | contractpharma.comCThe Yadot Group to Acquire Experiential Agency Socials DallasSeptember 16, 2024 | dallasinnovates.comDNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging By Nathan Reiff | August 4, 20253 Bullish Biotech Stocks With Explosive Growth TrendsBy Chris Markoch | July 21, 2025TFFP, EVFM, OGEN, and PTPI Company DescriptionsEvofem Biosciences NASDAQ:EVFM$0.0094 0.00 (-3.09%) As of 08/15/2025 03:52 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Oragenics NYSE:OGEN$1.15 -0.04 (-3.36%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$1.17 +0.02 (+1.74%) As of 08/15/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Petros Pharmaceuticals NASDAQ:PTPI$0.03 0.00 (-1.29%) As of 08/15/2025 03:38 PM EasternPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.TFF Pharmaceuticals NASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore The Real Reason Ford Stock Is Rallying—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access